← Leaderboards
Wenge Zhu
George Washington University
$9,139,423
Attributed
$10,397,227
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,397,227 · 7
By mechanism
R01$9,665,170 · 6
R00$732,057 · 1
Top collaborators
- Shunqiang Li3 shared
- Cynthia X Ma3 shared
Most similar at George Washington University
Same institution · by research overlap
- Shunqiang Li$3,121,300
- Cynthia X Ma$3,639,182
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoRegulationMolecularPathway InteractionsSiteDna BiosynthesisInnovationPhosphorylationProteinsMediatingGenesResistanceDna DamageResponseMalignant NeoplasmsCancer CellGenome StabilityPharmaceutical PreparationsPlayOncogenesRepairedMultidisciplinaryNovel StrategiesIn Vitro
Grant awards (26)
Regulation of resistance to CDK4/6 inhibitor in breast cancer$633,959
R01 · FY2025 · CA · contact PI
The role of And-1 in R-loop and endocrine resistance in breast cancer$557,797
R01 · FY2025 · CA · contact PI
The role of And-1 in nucleotide excision repair$455,808
R01 · FY2025 · CA · contact PI
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer$435,940
R01 · FY2025 · CA · contact PI
Regulation of resistance to CDK4/6 inhibitor in breast cancer$602,262
R01 · FY2024 · CA · contact PI
The role of And-1 in nucleotide excision repair$433,018
R01 · FY2024 · CA · contact PI
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer$414,143
R01 · FY2024 · CA · contact PI
Regulation of resistance to CDK4/6 inhibitor in breast cancer$650,485
R01 · FY2023 · CA · contact PI
The role of And-1 in nucleotide excision repair$446,691
R01 · FY2023 · CA · contact PI
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer$427,221
R01 · FY2023 · CA · contact PI
The role of And-1 in nucleotide excision repair$455,808
R01 · FY2022 · CA · contact PI
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer$427,218
R01 · FY2022 · CA · contact PI
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer$435,940
R01 · FY2021 · CA · contact PI
The Role of And-1 in DNA Damage Response$328,888
R01 · FY2018 · CA · contact PI
The Regulation of Cisplatin resistance in ovarian cancer$328,888
R01 · FY2018 · CA · contact PI
The Regulation of Cisplatin resistance in ovarian cancer$328,888
R01 · FY2017 · CA · contact PI
The Role of And-1 in DNA Damage Response$328,888
R01 · FY2017 · CA · contact PI
The Role of And-1 in DNA Damage Response$328,888
R01 · FY2016 · CA · contact PI
The Regulation of Cisplatin resistance in ovarian cancer$328,888
R01 · FY2016 · CA · contact PI
The Regulation of Cisplatin resistance in ovarian cancer$328,888
R01 · FY2015 · CA · contact PI
The Role of And-1 in DNA Damage Response$328,888
R01 · FY2015 · CA · contact PI
The Role of And-1 in DNA Damage Response$328,888
R01 · FY2014 · CA · contact PI
The Regulation of Cisplatin resistance in ovarian cancer$328,888
R01 · FY2014 · CA · contact PI
DNA Replication Control and Its Application to Selective Killing of Cancer Cells$241,529
R00 · FY2012 · CA · contact PI
DNA Replication Control and Its Application to Selective Killing of Cancer Cells$241,529
R00 · FY2011 · CA · contact PI
DNA Replication Control and Its Application to Selective Killing of Cancer Cells$248,999
R00 · FY2010 · CA · contact PI